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'e recent introduction of the “precision medicine” concept in oncology pushed cancer research to focus on dynamic measurable
biomarkers able to predict responses to novel anticancer therapies in order to improve clinical outcomes. Recently, the in-
volvement of extracellular vesicles (EVs) in cancer pathophysiology has been described, and given their release from all cell types
under speciﬁc stimuli, EVs have also been proposed as potential biomarkers in cancer. Among the techniques used to study EVs,
ﬂow cytometry has a high clinical potential. Here, we have applied a recently developed and simpliﬁed ﬂow cytometry method for
circulating EV enumeration, subtyping, and isolation from a large cohort of metastatic and locally advanced nonhaematological
cancer patients (N� 106); samples from gender- and age-matched healthy volunteers were also analysed. A large spectrum of
cancer-related markers was used to analyse diﬀerences in terms of peripheral blood circulating EV phenotypes between patients
and healthy volunteers, as well as their correlation to clinical outcomes. Finally, EVs from patients and controls were isolated by
ﬂuorescence-activated cell sorting, and their protein cargoes were analysed by proteomics. Results demonstrated that EV counts
were signiﬁcantly higher in cancer patients than in healthy volunteers, as previously reported. More interestingly, results also
demonstrated that cancer patients presented higher concentrations of circulating CD31+ endothelial-derived and tumour cancer
stem cell-derived CD133 +CD326- EVs, when compared to healthy volunteers. Furthermore, higher levels of CD133 +CD326−
EVs showed a signiﬁcant correlation with a poor overall survival. Additionally, proteomics analysis of EV cargoes demonstrated
disparities in terms of protein content and function between circulating EVs in cancer patients and healthy controls. Overall, our
data strongly suggest that blood circulating cancer stem cell-derived EVsmay have a role as a diagnostic and prognostic biomarker
in cancer.
1. Introduction
'e oncological therapies have profoundly changed in the
last years, due to a better comprehension of the biological
processes leading to tumour development and progression.
Old therapeutic paradigms have been overcome by the
concept of “precision medicine,” which aims for the ad-
ministration of tailored therapies. Accordingly, cancer
patients greatly beneﬁt from the availability of novel tissue
and blood biomarkers able to better predict responses to
novel anticancer therapeutics and improve clinical out-
comes in selected patient populations. Nevertheless, the
diagnosis, treatment, and follow-up of cancer patients still
suﬀer from the lack of dynamic measurable indicators of
tumour pathologic processes and pharmacological
responses.
'e last decades have seen a growing interest in the
involvement of extracellular vesicles (EVs) in cancer
physiopathology, and their potential role as cancer bio-
markers has been underlined [1–3].
EVs are particles naturally delivered into the extracel-
lular microenvironment, containing a rich cargo of DNA,
RNA, miRNAs, proteins, lipids, and metabolites [4, 5].'ree
main subtypes of EVs have been described, based on their
size and biogenesis: exosomes, ectosomes, also known as
microvesicles (MVs) or microparticles, and apoptotic
bodies. Exosomes originate from the endosomal system, and
their diameter ranges from 30 to 150 nm. EVs are released by
outward budding of the plasma membrane and measure 100
to 1000 nm in diameter. Apoptotic bodies, which are pro-
duced by cells destined to programmed cell death, are
heterogeneous in size with a diameter ranging from 200 to
5000 nm [6].
Several studies have described the role of EVs as me-
diators in the intercellular crosstalk for both short- and
longer-distance signalling [7–12]. Moreover, the transfer of
molecular cargoes promotes diﬀerent target cell responses,
modifying the microenvironment and modulating the im-
munological machinery [13].
It has been demonstrated that EVs are involved in the
pathogenesis of a number of diseases, including cancer
[2, 9, 14, 15]. Both in vitro and in vivo studies have elucidated
the active role of EVs in cancer biology. In particular, EVs
participate in angiogenesis, tumour progression and me-
tastasis, tumour-stroma interactions, and further biological
processes [16–23]. Several evidences suggest that tumour
cells produce higher numbers of EVs as compared with
nonmalignant cells [24].
Interestingly, tumour-derived EVs harbour an enriched
protein and genetic cargo when compared with EVs derived
from normal cells [25, 26]. Based on these observations,
peripheral blood circulating EVs can be recognised as a
ﬂourishing source of potential biomarkers [27–31] and, in
this context, a phenotypical characterisation of blood cir-
culating tumour-derived EVs, based on the analysis of
cancer-related surface protein expression has been
attempted [32–34]. Furthermore, recent in vivo studies have
demonstrated a possible prognostic and predictive role of
EV subtypes in cancer patients [34–37].
Currently, researchers are producing a huge eﬀort for the
identiﬁcation of new disease-related EV phenotypes, pos-
sibly useful for the development of new therapeutic ap-
proaches [38, 39]. Indeed, larger EVs can be easily isolated
from peripheral blood and characterized by multiple tech-
niques, such as ﬂow cytometry [7–10, 14]. For this reason,
the identiﬁcation and characterisation of peripheral blood
circulating cancer-related EVs have been proposed as a new
method of liquid biopsy, which possibly allows to avoid the
more invasive tissue biopsy, to extend the beneﬁts of mo-
lecular characterization to early diagnosis, and to monitor
temporal and spatial heterogeneity of tumour cells.
Given the increasing relevance of this research ﬁeld, we
carried out an observational prospective study, in order to
shed light on the role of tumour-derived EVs, both as di-
agnostic and prognostic markers in cancer patients. We
focused on ﬂow cytometry identiﬁcation and proteomics
characterisation of peripheral blood circulating EVs with the
aim to identify new possible markers to detect and char-
acterise circulating cancer-related EV subpopulations
through a comparative analysis of EV subtypes in metastatic
cancer patients and healthy volunteers. Finally, these ﬁnd-
ings have been correlated with the clinical outcomes of
patients, in order to explore the potential prognostic and
predictive role of EVs.
2. Materials and Methods
2.1. Patients. 'is observational prospective study was ap-
proved by the local ethics committee. All subjects involved in
the study gave a written informed consent. Peripheral blood
(PB) samples were obtained from 106 metastatic and locally
advanced nonhaematological cancer patients and 25 healthy
volunteers, recruited from the Clinical Oncology Unit (“SS.
Annunziata” Hospital, Chieti, Italy). 'e demographic
characteristics of all enrolled subjects were summarized in
Supplementary Table 1. Samples were collected at the
baseline, before the ﬁrst or the subsequent cancer treatment
lines, and at the time of the ﬁrst radiological assessment. PB
samples were collected both for patients and for healthy
volunteers in the same conditions.
2.2. Extracellular Vesicle Staining for Flow Cytometry.
From each enrolled subject, two sodium citrate tubes
(Becton Dickinson Biosciences (BD), San Jose, CA, USA, Ref
454387) were used to collect the peripheral blood samples,
using 21 G needles. Samples were processed within 4 hours
from bleeding. 'e ﬁrst harvested tube of PB was discarded
to minimize venepuncture-induced vascular damage eﬀects
[40, 41]. Of note, phalloidin was added to the reagent mix to
stain events characterized by damaged membranes, given its
binding to F-actin [10, 42]. 'e staining was performed
following an already described protocol [10]. In detail, as the
ﬁrst step, the reagent mix was prepared by adding FITC-
conjugated phalloidin (when needed) and LCD (BD
Biosciences–Catalogue, #626267, Custom Kit), and all re-
agents detailed in Table 1 (Panel 1 or Panel 2 or Panel 3) were
added to 195 μl of PBS 1X, and then 5 μl of whole blood was
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added to the mix. After 45min of staining (RT, in the dark),
500 μl PBS 1X was added to each tube, and 1× 10 [6] events/
sample were recorded by ﬂow cytometry (FACSVerse, BD
Biosciences).
To avoid the immune complex formation and the un-
speciﬁc background linked to the antibody aggregation, each
antibody stock solution was centrifuged before its use, at
21,000g for 12 minutes.
2.3. Extracellular Vesicle Flow Cytometry Acquisition. 'e
trigger threshold was set on the channel in which the
LCD emits (allophycocyanin (APC) channel; threshold
value� 200/262,144), while in order to avoid the loss of the
events of interest, no threshold on scatter parameters was
applied. 'e signal pulse height (H) was measured and
represented for the forward scatter (FSC), the side scatter
(SSC), and any ﬂuorescent signal. EV scatter properties were
established and validated by the Rosetta Calibration System
(Exometry, Amsterdam, NL), as previously described [43],
and by running Megamix-Plus beads (Byocitex, Marseille,
France) at the same photomultiplier (PMT) ampliﬁcation
used for EV detection. Each antibody/reagent used in the
panels was titrated (8-point titration) under the assay
conditions; dilutions were established based on achieving
the optimal signal to noise ratio [44]. 'e evaluation of
nonspeciﬁc ﬂuorescence was obtained by acquiring Fluo-
rescence Minus One (FMO) and isotype controls [45, 46].
Reagent-only and buﬀer-only controls were also ana-
lysed, and we observed that establishing the APC channel
trigger threshold as mentioned above, in both cases, pro-
duced the acquisition of almost no events during the time
interval needed for the sample acquisition (∼1 minute). A
sample treated by a solution of 1% Triton X-100 was ac-
quired in order to verify that LCD staining targets intact
EVs.
Compensation was assessed using CompBeads (BD) and
single-stained ﬂuorescent samples. Data were analysed using
FACSDiva v 6.1.3 (BD), FACSuite v 1.0.6.5230 (BD), and
FlowJo v 10 (TreeStar, Ashland, OR, USA) software. Ex-
tracellular vesicle numbers were obtained by the volumetric
count. 'is polychromatic ﬂow cytometry method allowing
the analysis of EV concentrations and subtyping has been
recently patent submitted (European patent application
number EP19164567.0).
2.4. Gating Strategy for Extracellular Analysis and Subtyping
2.4.1. Panel 1. Supplementary Figure 1A shows a dotplot
representing the SSC-H and the FSC-H, used to set a region
under the one in which platelets (PLTs) fall. Such a region
was deﬁned as a “platelet-free area.” Events of the “platelet-
free area” were then represented on an LCD-H/Phalloidin-H
dotplot, and EVs were identiﬁed as LCD-positive/phalloi-
din-negative dots (Supplementary Figure 1B). 'erefore,
EVs (LCD+/phalloidin− events) were analysed on a CD45-
H/CD133-H dotplot, and CD45 + events were gated (Sup-
plementary Figure 1C). A CD45-negative logical gate was
set, and the resulting population was plotted on a CD326-H/
CD133-H dotplot (Supplementary Figure 1D). Several EV
phenotypes were here identiﬁed (CD133+/CD326-;
CD133+/CD326+; CD133-/CD326+).
2.4.2. Panel 2. EVs were identiﬁed as LCD-positive/phal-
loidin-negative events, falling in the “platelet-free area,” as
described in Supplemental Figure 1A-B. EVs were then
represented on a CD31-H/CD41a-H dotplot (Supplemen-
tary Figure 1E), and events showing the CD31+/CD41a +
phenotype were identiﬁed as platelet-derived EVs (PLT-
EVs). A PLT-EVs-negative logical gate was set, and the
resulting population was plotted on a CD45-H/CD31-H
dotplot (Supplementary Figure 1F). CD45 + events were
identiﬁed as leukocyte-derived EVs, while the CD31+/
CD45− compartment was deﬁned as the endothelial-derived
EV population.
2.4.3. Panel 3. Events of the “platelet-free area” were
identiﬁed as described in Supplementary Figure 1A and
then represented on an LCD-H/CD235a-H dotplot; given
that the majority of phalloidin + events falling in this area
Table 1: Reagent list-Panel 1-Panel 2-Panel 3.
Reagent Fluorochrome/reagent Vendor Clone Catalog number Amount per test
Panel 1
CD133/2 PE Miltenyi Biotec 293C3 130-113-186 1 μl
EpCAM PerCP-Cy5.5 BD Biosciences (EBA-1) 347199 5 μl
CD45 BV510 BD Biosciences HI30 626266 (custom kit) 5 μl
Panel 2
CD41a PE BD Biosciences HIP8 626266 (custom kit) 5 μl
CD31 PE-Cy7 BD Biosciences WM59 626266 (custom kit) 5 μl
CD45 BV510 BD Biosciences HI30 626266 (custom kit) 5 μl
Panel 3
CD90 FITC BD Biosciences 5E10 555595 1 μl
CD29 PE BD Biosciences MAR4 555443 3 μl
CD45 BV510 BD Biosciences HI30 626266 (custom kit) 5 μl
CD235a BV421 BD Biosciences GA-R2 (HIR2) 562938 5 μl
FITC� ﬂuorescein isothiocyanate; PE�R-phycoerythrin; PerPC-Cy5.5� peridinin-chlorophyll proteins-cyanine 5.5; PE-Cy7�PE-Cyanine 7, BV�Brilliant
Violet.
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results in CD235a+ (not shown), here EVs were identiﬁed
as LCD-positive/CD235a-negative dots (Supplementary
Figure 1G). 'ose events were analysed on a CD45-H/
CD90-H dotplot, and CD45+ events were gated (Supple-
mentary Figure 1H). A CD45-negative logical gate was set,
and the resulting population was plotted on a CD29-H/
CD90-H dotplot (Supplementary Figure 1I). Several EV
phenotypes were here identiﬁed (CD90+/CD29-; CD90+/
CD29+; CD90-/CD29+).
2.5. Extracellular Vesicle Separation by Fluorescence-Acti-
vated Cell Sorting. Extracellular vesicles were separated
(100 μm nozzle) by using a FACSAria III cell sorter (BD
Biosciences) from whole peripheral blood samples on the
basis of their positivity to the LCD and negativity to
phalloidin, combined with their SSC-H and FSC-H fea-
tures. 'e postsorting purity was assessed by reanalysing
puriﬁed samples, as recommended, and purity was con-
stantly higher than 90% [47]. As recently published, the EV
separation method described here allowed the obtainment
of EV preparations that resulted free from soluble circu-
lating contaminants that usually aﬀect EV samples puriﬁed
using state-of-the-art techniques (i.e., ultracentrifugation)
[10].
2.6. Extracellular Vesicle Label-Free Proteomics. Two million
pooled puriﬁed EVs from lung cancer patients were
employed for proteomics investigation. As already pub-
lished, the number of separated EVs (obtained by the
counting performed using the ﬂuorescent-activated cell
sorter) can be used as a normalization parameter for pro-
teomics analyses [7, 10]. A typical digestion protocol of
ﬁlter-aided sample preparation (FASP) was carried out
overnight at 37°C using trypsin (Promega, Madison, WI).
EV-digested proteins from each sample were analysed in
triplicate by liquid chromatography tandem mass spec-
trometry (LC-MS/MS), using a Proxeon EASY-nLCII
('ermo Fisher Scientiﬁc, Milan, Italy) chromatographic
system coupled to a Maxis HD UHR-TOF (BrukerDaltonics
GmbH, Bremen, Germany) mass spectrometer. Peptides
were loaded on the trapping EASY-Column C18 (2 cmL,
100 μm ID, 5 μmps, 'ermo Fisher Scientiﬁc) and then
separated on an Acclaim PepMap100 C18 (75 μm ID,
25 cmL, 5 μmps, 'ermo Fisher Scientiﬁc) nanoscale
chromatographic column. 'e ﬂow rate was set at 300 nL/
min, with a total run time of 90 minutes, as already described
[7]. 'e mass spectrometer was operated in positive-ion
polarity and auto MS/MS mode (Data Dependent Acquis-
ition(DDA)), using N2 as collision gas for CID fragmen-
tation. Precursors in the range 350 to 2,200m/z (excluding
1,220.0–1,224.5m/z) with a preferred charge state from +2 to
+5 (excluding singly charged ions) and absolute intensity
above 4,706 counts were selected for fragmentation in a
maximum cycle time of 3 seconds. Precursors were actively
excluded from selection for 30 seconds after acquiring.
Isolation width and collision energy for MS/MS fragmen-
tation were set according to the mass and charge state of the
precursor ions, with in-source reference lock mass
(1,221.9906m/z) online acquisition, throughout the runs.
2.7. Data Processing of Label-Free Proteomics Analysis.
Quantitative data analysis was performed by a free com-
putational proteomics platform, MaxQuant version 1.3.3.4.
(Max-Planck Institute for Biochemistry, Martinsried, Ger-
many), using the raw data ﬁle of MS/MS spectra. Peak lists,
generated in MaxQuant, were searched using Andromeda
[48] peptide search engine against the UniProt database
(released 2018_04, taxonomy Homo sapiens; 20,874 protein
entries) supplemented with frequently observed contami-
nants and containing forward and reverse sequences.
Multiplicity was set to one because a label-free quantiﬁcation
was performed. Trypsin digestion mode was speciﬁed with
up to two missed cleavages. Carbamidomethylation of
cysteines (C) was deﬁned as ﬁxed modiﬁcation and used in
protein quantiﬁcation, while oxidation of methionines (M)
was set as variable modiﬁcation. Minimum peptide length of
7 amino acids was set, and the search space was limited to a
maximum peptide mass of 4600Da. MaxQuant uses indi-
vidual mass tolerances for each peptide; the initial maximum
precursor mass tolerances were set by default to 0.07Da in
the ﬁrst search and 0.006Da in the main search, and the
fragment mass tolerance was set to 0.1Da. A retention time
tolerance of 2min was used to align any time shift in ac-
quisition between samples. False discovery rate (FDR) at the
protein level was set at 2%, while at the peptide level was set
at 1%. Protein identiﬁcation was performed with at least one
unique peptide. Intensity-based absolute quantiﬁcation
(iBAQ) in MaxQuant was performed on the identiﬁed
peptides to quantify protein abundance in mixture.
2.8. Statistical Analysis. Statistical analysis was performed
using SPSS version 21.0 and GraphPad Prism (GraphPad
Software Inc., La Jolla, CA, USA) software. Population data
were provided as median with 95% conﬁdence interval. A
Fisher’s exact test was used to evaluate diﬀerences in terms of
age and sex between healthy control subjects and cancer
patients, as indicated.
Comparison of EV counts was evaluated by non-
parametric Kruskal–Wallis H test, as appropriated. Median
overall survival (OS) was evaluated using the Kaplan–Meier
curve estimator. In survival analysis, events were established
as cancer-related death. 'e logrank test was used to
compare median OS. A Cox proportional hazards model was
employed to calculate the hazard ratio. 'e data cutoﬀ was
set on February 2019.
'e statistical signiﬁcance was accepted for p< 0.05.
Disease control rate (DCR) was used to deﬁne re-
sponders and nonresponders and relative proportions and
ratios according to CD133 +CD326− EV count threshold
were evaluated. Cutoﬀ values were generated with the re-
ceiving operator characteristic (ROC) curve, and the cor-
responding area under the curve (AUC) was reported, as
indicated. Optimal cutoﬀ values of ROC curves were
identiﬁed through the Youden index.
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3. Results
3.1. EVs and EV Subtypes in Cancer Patients. Peripheral
blood circulating EVs were analysed in patients with ad-
vanced cancer and in healthy volunteers; both the total
amount of EVs and the concentrations of diﬀerent EV
subpopulations were analysed.
A list of solid tumour immunophenotypical markers was
tested according to the literature [49–52]. 'is list included
the following: EpCaM (CD326), CD133, CD90, and CD29. A
number of diﬀerent EV subpopulations were established by
combining diﬀerent markers (CD133 +CD326− , CD133−
CD326+, CD133 + CD326+, CD90 + CD29− , CD29 +
CD90− , and CD90 + CD29+). Peripheral blood circulating
leukocyte-derived (CD45+) and endothelial-derived (CD31+/
CD45-/CD41a-) EV levels were also evaluated.
Conﬁrming previously reported data [53], we demon-
strated that the overall blood concentration of EVs resulted
signiﬁcantly higher in cancer patients than in healthy
volunteers (cancer patients: median� 14,308 EVs/μl; 95% CI
4,368–70,763; healthy volunteers: median� 5,207 EVs/μl;
95% CI 1751–13531; p value� 0.000001). We further
stratiﬁed the cancer patient population according to the
primary tumour site. As shown in Figure 1 and reported in
Table 2, higher concentrations of total EVs were detected in
all cancer patient groups when paralleled to their age- and
gender-matched healthy controls.
We further analysed the diﬀerences in EV subtype
concentrations between cancer patients and healthy con-
trol subjects (Table 2 and Figure 1). Flow cytometry data
revealed that cancer patients presented higher concentra-
tions of CD31+ endothelial-derived and CD133 +CD326−
tumour cancer stem cell-derived EVs, when compared to
healthy volunteers. A cutoﬀ value of CD133 +CD326− EV
levels distinguishing cancer patients and healthy controls
has been identiﬁed (82.5 EVs/μl) with a sensitivity and
speciﬁcity of 0.69 and 0.84, respectively (Supplementary
Figure 2C).
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Figure 1: EV concentrations in cancer patients and healthy volunteers. Peripheral blood EV concentrations from healthy subjects and
tumour patients (overall, lung, breast, colon, and other tumors) were obtained and analysed. Diﬀerences of total EVs (a), CD31+ (b), and
CD326− CD133 +EVs (c) between patients and healthy controls (HC) were calculated and reported as box plots. Horizontal black lines
represent median values. Statistical comparison was performed by the Kruskal–Wallis H test. Extreme values were not shown.
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Higher concentrations of CD31+EVs have been identiﬁed
in breast and colorectal patients, while higher concentrations
of CD133+CD326− EVs have been observed in lung, breast,
and colorectal cancer patients. Notably, a ten-fold increase of
the concentrations of the epithelial committed cancer stem
cell-derived EV subpopulation (CD133+/CD326+) was de-
tected in lung cancer patients, when compared to healthy
subjects, although such a subset did not signiﬁcantly change
between all cancer patients and healthy controls. Breast cancer
patients also displayed lower levels of CD29+CD90+/− and
CD326+CD133− than healthy subjects.
3.2. Prognostic Role of EVs in Cancer Patients. We then in-
vestigated whether EV concentrations could be related to
clinical outcomes. Based on the results of the comparative
analysis between cancer patients and healthy volunteers, we
focused on a possible correlation between total, CD31 +, or
CD133 +CD326− EV concentrations and the overall sur-
vival of the total cancer patient cohort or of the cancer
subgroups (Figure 2). We observed that total EV concen-
tration was not signiﬁcantly related to diﬀerences in overall
survival (OS), when all cancer patients were analysed (HR
1.36, 95% CI 0.81–2.30, p � 0.25). A higher median OS was
detected in patients displaying lower peripheral blood EV
counts, but such a survival advantage was not statistically
signiﬁcant in the overall cancer population (Supplementary
Table 2).'e same ﬁndings were obtained when CD31 + EVs
were analysed (Supplementary Table 2). Although patients
with a lower number of circulating CD31 + EVs (<120 EVs/
μl) presented a higher survival probability, this result was not
supported by statistical signiﬁcance in the overall population
(Supplementary Table 2).
Otherwise, a remarkable and statistically signiﬁcant
diﬀerence in OS was detected between the two groups of
patients that displayed diﬀerent concentrations of
CD133 +CD326− EVs in the whole cancer population (HR
2.79; 95% CI 1.51–5.17, p � 0.001; Supplementary Table 2/
Figure 2). 'e cutoﬀ value between these two groups was
118.5 EVs/μl. Median OS was not reached in the group of
patients with low CD133 +CD326− EV counts, compared to
a median OS of 8 months for patients with higher con-
centrations of CD133 +CD326− EVs (Figure 2(a) and
Supplementary Table 2). Of note, no diﬀerences in terms of
age or gender between these two groups of patients were
evidenced (Supplementary Table 3). Furthermore, we
stratiﬁed our survival analysis according to the cancer
subgroups, focusing our attention on lung and colon cancer
patients that resulted in the most copious cohorts in our
study population (as shown in Supplementary Table 2).
Table 2: Analysis of EV concentrations in cancer patients and
healthy volunteers.
EVs/μl (CI 95%) p value
Total EV
Controls 5207 (1751–13531)
Cancer 14308 (4368–70763) 0.000001
Lung cancer 9600 (3867–75021) 0.0001
Colorectal cancer 19044 (5257–1745393) 0.000001
Breast cancer 17437 (8079-NE) 0.001
Other 19012 (8047-NE) 0.0000001
CD31+
Controls 70 (7–268)
Cancer 168 (0.5–1297) 0.001
Lung cancer 123 (5–1021) 0.058
Colorectal cancer 168 (1–2826) 0.007
Breast cancer 371 (39-NE) 0.003
Other 411 (0-NE) 0.001
CD90-CD29+
Controls 150 (11–1573)
Cancer 168 (1–2924) 0.668
Lung cancer 297 (10–2467) 0.165
Colorectal cancer 279 (0–4347) 0.515
Breast cancer 39 (23-NE) 0.02
Other 83 (0-NE) 0.273
CD326-CD133+
Controls 34 (0–260)
Cancer 194 (0–2286) 0.00001
Lung cancer 151 (4–3376) 0.001
Colorectal cancer 123 (0–2827) 0.006
Breast cancer 262 (55-NE) 0.003
Other 300 (0-NE) 0.00001
CD326 +CD133-
Controls 742 (20–2545)
Cancer 554 (15–2546) 0.155
Lung cancer 650 (50–2188) 0.476
Colorectal cancer 899 (5–7678) 0.775
Breast cancer 150 (10-NE) 0.003
Other 177 (0-NE) 0.015
LEUKO-EV
Controls 238 (37–1721)
Cancer 265 (42–1351) 0.529
Lung cancer 328 (34–1680) 0.086
Colorectal cancer 274 (47–2416) 0.522
Breast cancer 66 (38-NE) 0.036
Other 182 (64-NE) 0.407
CD90 +CD29-
Controls 280 (24–3341)
Cancer 143 (6–5606) 0.161
Lung cancer 62 (0–2276) 0.058
Colorectal cancer 145 (8.2–17356) 0.437
Breast cancer 193 (24-NE) 0.342
Other 182 (17-NE) 0.980
CD90 +CD29+
Controls 134 (11–571)
Cancer 84 (0–615) 0.110
Lung cancer 87 (0–675) 0.232
Colorectal cancer 109 (7–788) 0.543
Breast cancer 9 (0-NE) 0.001
Other 82 (6-NE) 0.160
CD326 +CD133+
Controls 17 (0–83)
Table 2: Continued.
EVs/μl (CI 95%) p value
Cancer 63 (0–739) 0.124
Lung cancer 172 (0–1312) 0.002
Colorectal cancer 87 (0–2670) 0.204
Breast cancer 0 (0-NE) 0.002
Other 5 (0-NE) 0.435
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We demonstrated that lung cancer patients with high
CD133 + CD326− EV concentrations had 2.6 times higher
risk of death, compared to those with lower
CD133 + CD326− EV peripheral blood concentrations
(HR 2.60; 95% CI 1.26–5.37; p � 0.01; Figure 2(b), Sup-
plementary Table 2). When we further stratiﬁed the pa-
tients for the line of therapy, we observed that this
advantage was also conﬁrmed in the group of treatment-
naı¨ve lung cancer patients (data not shown). No diﬀerence
in terms of gender and age distribution between the two
groups of lung cancer patients was demonstrated (Sup-
plementary Table 3).
A possible correlation between CD133 +CD326− EV
levels and clinical beneﬁt from cancer treatments was ex-
plored both in the overall cohort and in lung cancer patients.
We observed that almost a 60% of patients who achieved a
response or a stable disease after anticancer therapy pre-
sented lower circulating EV levels at the baseline (odds ratio
1.83; 95% CI 1.30–13.8; p � 0.0003; Supplementary Table 4).
Additionally, higher CD133 +CD326− EV concentrations
were detected in a large proportion of patients who expe-
rienced a progressive disease (78.4%, Supplementary Ta-
ble 4). Similar ﬁndings were reported for the lung cancer
group of patients (Supplementary Table 4).
As peripheral blood samples were collected at the
baseline and at the ﬁrst disease radiological evaluation,
modiﬁcations in EV levels during cancer treatment were
analysed (Supplementary Tables 5 and 6). In particular, we
studied how the variations in terms of CD133 +CD326− EV
levels were related to the disease status. Interestingly, we
observed that decreased EV levels were frequently related to
a progressive disease at the time of the ﬁrst radiologic
evaluation (odds ratio 0.33; 95% CI 0.13–0.84; p � 0.019).
Accordingly, the 66.7% of responder patients presented
increasing or stable CD133 +CD326− EV levels (odds ra-
tio 1.46; 95% CI 1.04–2.05; p � 0.019, Supplementary
Table 7).
3.3. Analysis of EV Protein Cargo in Lung Cancer Patients.
EV samples from a selected and well-classiﬁed cohort of
patients aﬀected by lung cancer (N � 6) were pulled, and
related protein cargoes were analysed and compared to
healthy volunteers (N � 3). Total and intact EVs were
identiﬁed as LCD+/phalloidin− events and separated by
ﬂuorescence-activated cell sorting. A high level of purity
was reached (>90%), and 2.0 ×10 [6] sorted EVs from each
condition were analysed in triplicate by a shotgun pro-
teomics approach, as already described [10]. 'e list of the
identiﬁed proteins, in at least one replicate for each
condition, was reported in Supplementary Table 8 and
mainly classiﬁed as “vesicle-mediated transport” (GO:
0016192; p � 1.43e− 20) as reported in Figure 3 (red dots),
conﬁrming the eﬃciency of the used isolation protocol. As
reported in Supplementary Figure 3, we identiﬁed 48 EV
proteins in healthy subjects and 42 proteins in EVs from
cancer patients (Supplementary Figure 3A; Supplemen-
tary Table 8). Interestingly, six proteins were identiﬁed
only in cancer EVs and three of them resulted from the
“cell-cell adhesion” processes, as reported in Supple-
mentary Figure 2B; (red dots, p � 0.0023). Otherwise,
twelve proteins, most of them related to the “regulation
of peptidase activity” (Supplementary Figure 3; GO:
0052547) process, were identiﬁed only in EVs from healthy
volunteers.
Finally, an Ingenuity Pathway analysis (IPA), based on
quantitative proteomics data of all identiﬁed proteins, was
carried out. Data reported in Figure 4 highlight that more
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were calculated on the basis of the peripheral blood concentrations of CD326-CD133 +EVs. (b) 'e Kaplan–Meier survival curves for lung
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than 30 identiﬁed proteins allowed the activation of the
“Liver Lesion,” as toxic function in cancer EVs
(p � 9.78E − 05, z-score� 2.621). 'e IPA upstream regu-
lator analysis, based on the prior knowledge of expected
eﬀects between transcriptional regulators and their target
genes [54], was then performed. Results showed that the
“zinc ﬁnger protein 106,” which is involved in the insulin
receptor signalling pathway, was the main activated up-
stream in cancer (p value� 2.9E − 06, z-score� 2.0).
4. Discussion
Cancer is the second leading cause of death worldwide [55].
New biomarkers are needed to improve cancer diagnosis
and the evaluation of patient outcomes [56]. Extracellular
vesicles are released by all cell types, reﬂecting the biological
frame of the cellular complexity of each patient [57]. EVs are
able to transport speciﬁc DNA fragments, RNAs, mi-RNAs,
and proteins to target cells. 'e EV biological content and
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the physical durability of EVs make them a high suitable and
promising material to be employed as a stable and sensitive
source of cancer biomarkers [58]. 'us, the characterisation
of EV biological complexity may represent a reliable sur-
rogate of the patient pathophysiological status. Few studies
have been published on the ex-vivo characterisation of pe-
ripheral EV subtypes in cancer patients [32–34]. Moreover,
all state-of-the-art protocols rely on a number of pre-
analytical enrichment steps which induce artefact genera-
tion.We have developed a simpliﬁed ﬂow cytometry method
for EV characterisation that does not require any pre-
analytical enrichment procedure, thus relying on non-
manipulated material and allowing a more reliable picture of
the patient condition [7, 10, 59]. Such a method has been
applied here to analyse EV concentrations and phenotypes
in a large cohort of cancer patients. Interestingly, we
demonstrated that cancer patients displayed a signiﬁcantly
higher concentration of peripheral blood circulating EVs.
Given that the intercellular crosstalk is particularly active in
cancer, this strong exchange of information is probably
reﬂected by high circulating levels of EVs. 'is ﬁnding is in
agreement with the recent literature pointing out the
pathophysiological role of EVs as cancer hallmarks [57]. In
order to dissect the EV involvement in cancer complexity,
we analysed diﬀerent EV subtypes, possibly linked to tu-
mour pathogenesis. In such a context, it was interesting to
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note that endothelial-derived EVs were signiﬁcantly in-
creased, in terms of concentration, in cancer and especially
in colon cancer patients. It is well known that colon cancer is
highly dependent on tumour neovasculogenesis [60], and we
plan to enlarge our study cohort of colon cancer patients in
order to understand the potential of endothelial EVs as
biomarkers to predict or monitor the antiangiogenetic
therapy outcomes.
On the other hand, our data strongly suggest a role for
CD133 +CD326− EVs in the context of cancer development.
As a matter of fact, CD133 was originally identiﬁed as a
surface antigen of hematopoietic stem cells and as a marker
for other embryonic epithelia. Currently, CD133, in asso-
ciation with the lack of CD326 [61], is broadly recognised as
a stem cell marker, even though its biological function is still
not globally understood [49]. Indeed, EVs deriving from
cancer stem cells display the same phenotype of their pa-
rental cells [62]. In this context, we demonstrated a statis-
tically signiﬁcant increase of CD133 +CD326− cancer stem
cell-derived EVs in cancer patients (p � 0.00001). A cutoﬀ
value of CD133 +CD326− EV levels distinguishing cancer
patients and healthy controls has been identiﬁed (82.5 EVs/
μl) with high sensitivity and speciﬁcity. 'is means that, if
conﬁrmed by further and enlarged studies, circulating
CD133 +CD326− EVs could represent a potential useful
tool for cancer screening and diagnosis. Moreover, our
ﬁndings suggest a strong correlation between
CD133 +CD326− EV concentrations and patient clinical
outcomes. In detail, high levels of cancer stem cell-derived
EVs (>118.5 EV/μl) in the whole cancer patient cohort were
associated with a poor prognosis, in terms of overall survival.
Moreover, CD133 +CD326− EV concentrations were also
related to the clinical response rate, given that high levels of
this EV subset characterized the majority of patients (78.4%)
who did not respond to anticancer therapies. 'ese ﬁndings
were obtained for the whole cohort of cancer patients and
were conﬁrmed when we analysed lung cancer patients
which resulted the most represented in our setting. 'ese
results were consistent with the poor prognostic role of
increased cancer tissue CD133 expression, already described
in several studies [63]. 'is suggests the possible active role
of the CD133 antigen in the pathophysiological mechanisms
of malignancies, and it strongly supports the idea that the
levels of CD133 + EVs circulating in the peripheral blood
possibly reﬂect the complex scenario characterizing the
cellular frameworks of the tumour.
As an opening approach for the molecular character-
isation of cancer EVs, we carried out a quantitative pro-
teomics analysis in lung cancer EVs, highlighting diﬀerential
protein expression that, in turn, could be involved in cancer-
related biological processes. In particular, Desmoplakin
(DSP), Desmocollin-1 (DSC1), Desmoglein-1 (DSG1), and
small proline-rich protein 2A (SPRR2A) were identiﬁed only
in lung cancer EVs and resulted from “cell-cell adhesion”
process that, as already described, plays a pivotal role in the
development and progression of cancer [64]. Moreover,
more than 30 identiﬁed proteins allowed the activation of the
“Liver Lesion” as a toxic function in cancer EVs. In-
terestingly, among the pooled and analysed subjects, one
patient presented multiple liver metastasis at the time of the
observation, while another patient has developed liver
metastases several months after blood sample collection.
However, further studies in larger cohorts of cancer patients
with liver metastasis are needed to understand the biological
and clinical implications of this ﬁnding.
Altogether, these results demonstrated that EVs could
represent a surrogate marker of the tumour complexity, able
to capture, in each moment, the development status of the
disease and/or the response to treatments.
'erefore, the study of phenotypes, concentrations, and
cargoes of the EVs could open a novel view of the liquid
biopsy of the future.
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Supplementary Table 1: patient characteristics. Supple-
mentary Table 2: survival analysis. Supplementary Table 3:
univariate analysis of CD133 +CD326− EVs. Supplementary
Table 4: clinical beneﬁt rate evaluated according to
CD133 +CD326-EV concentrations. Supplementary Ta-
ble 5: baseline EV concentrations in cancer patients. Sup-
plementary Table 6: EV concentrations in cancer patients at
the ﬁrst radiological evaluation. Supplementary Table 7:
variation of CD133 +CD326− EV levels respect to the
baseline concentration, evaluated according to the clinical
beneﬁt response. Supplementary Table 8: list of proteins
identiﬁed in EV isolated from healthy control subjects (8A)
and from lung cancer patients (8B). Supplementary Figure 1
Panel 1: (A) A region (“platelet-free area”) under the one in
which platelets (PLTs) fall was drawn on a SSCH/FSC-H dot-
plot. (B) 'e “platelet-free area” events were then repre-
sented on an LCD-H/Phalloidin-H dotplot and EVs were
identiﬁed as LCD-positive/phalloidin-negative dots. (C) EVs
(LCD+/phalloidin− events) were analysed on a CD45-H/
CD133-H dotplot and CD45 + events were gated; a CD45-
negative logical gate was then set, and the resulting pop-
ulation was plotted on a (D) CD326-H/CD133-H dotplot,
where CD133+/CD326− , CD133+/CD326+, and CD133− /
CD326 +EVs were identiﬁed. Panel 2: (E) EVs identiﬁed as
shown in A and B were represented on a CD31-H/CD41a-H
dotplot, and events showing the CD31+/CD41a + phenotype
were identiﬁed as platelet-derived EVs (PLT-EVs); a PLT-
EVs-negative logical gate was set. (F) 'e PLT-EV-negative
population was plotted on a CD45-H/CD31-H dotplot, and
CD45 + events were identiﬁed as leukocyte-derived EVs,
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while the CD31+/CD45− compartment was deﬁned as the
endothelialderived EV population. Panel 3. (G) 'e
“platelet-free area” events were identiﬁed as described in A
and then represented on an LCD-H/CD235a-H dotplot; EVs
were identiﬁed as LCD-positive/CD235a-negative dots. (H)
'ose events were analysed on a CD45-H/CD90-H dotplot,
and CD45 + events were gated. A CD45-negative logical gate
was set. (I) 'e resulting population was plotted on a CD29-
H/CD90-H dotplot, where CD90+/CD29− , CD90+/CD29+,
and CD90− /CD29 + EVs were identiﬁed. Supplementary
Figure 2: ROC curves were calculated to determine the
power of total EV (a), CD31+ EV (b), and CD133 +CD326−
EV (c) concentrations as a discriminator of patients and
healthy volunteers. Supplementary Figure 3: (A) Venn di-
agram of the identiﬁed proteins in healthy control (HC)
pooled EVs and in lung cancer polled EVs. (B) 'ree of the
six proteins (reported as red dots) identiﬁed only in cancer
EVs resulted from the “cell-cell adhesion” process
(p � 0.0023). (C) Ten proteins identiﬁed only in EVs from
healthy volunteers resulted from the “regulation of peptidase
activity” (GO:0052547). (Supplementary Materials)
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